

******NOTE THAT IF YOU HAVE ALREADY RETURNED A SUPPORT UNDERTAKING, YOU ARE NOT REQUIRED TO RETURN ANOTHER UNDERTAKING AND WILL BE ENTITLED TO THE 2% EARLY CONSENT FEE PROVIDED THAT YOU REMAIN IN COMPLIANCE WITH THE TERMS OF THE SUPPORT UNDERTAKING, INCLUDING VOTING TO APPROVE THE APPLICABLE SCHEME.******

INSTRUCTIONS TO INVESTORS IN THE CATCO REINSURANCE OPPORTUNITIES FUND LTD.

ENTERING INTO AN INVESTOR UNDERTAKING

On September 27, 2021, Markel CATCo Investment Management Ltd. announced the terms of a transaction that provides for an early return of substantially all net asset value (NAV) to persons who are beneficially interested in the shares of CATCo Reinsurance Opportunities Fund Ltd. (the "**Public Fund**") and such persons, the "**Investors**") and also allows Investors to retain the right to receive any upside at the end of the current run-off period if currently held reserves are more than sufficient to pay claims (the "**Buy-Out Transaction**").

The announcement and additional information regarding the Buy-Out Transaction is available on the following website <https://catcobuyout.alixpartners.com>.

As part of the implementation of the Buy-Out Transaction, the Public Fund intends to propose a scheme of arrangement pursuant to Section 99 of the Companies Act (the "**Scheme**").

As described in the announcement, Investors in the Ordinary shares and C shares of the Public Fund are being offered the opportunity to accept the terms of an investor undertaking ("**Investor Undertaking**") pursuant to which they will commit to vote to approve the Scheme. Investors will become eligible to receive at completion of the Buy-Out Transaction an early consent fee equal to one per cent (1%) of the Investor's current NAV entitlement (the "**Early Consent Fee**") by accepting the terms of the Investor Undertaking in accordance with the below instructions on or before 11:59 p.m. (Bermuda time) on October 22, 2021 or such later date as specified by the Public Fund (the "**Early Consent Deadline**") and complying with the terms of the Investor Undertaking, including timely voting in favour of the Scheme.

These instructions set out how Investors can confirm their acceptance of the Investor Undertaking.

You are being sent these instructions as the Public Fund believes that you are or may be an Investor entitled to vote on the Scheme, and/or are a nominee or custodian for an Investor or hold an interest in shares of the Public Fund on behalf of Investors. If you are holding interests in the Public Fund on behalf of one or more Investors, you should promptly forward a copy of these materials to all persons on whose behalf you hold an interest, so they may instruct you to enter into the Investor Undertaking on their behalf. If you have assigned, sold, or otherwise transferred, or assign, sell or otherwise transfer, your interests as an Investor before the Early Consent Deadline, you must forward these materials at once to the person or persons to whom you have assigned, sold or otherwise transferred, or assign, sell or otherwise transfer, your interests as an Investor.

Please note that although these instructions contain brief descriptions of some of the terms of the Investor Undertaking, Investors should not rely on these descriptions alone and should instead review the Investor Undertaking, which is available on the transaction website (<https://catcobuyout.alixpartners.com>). If there are any discrepancies between these instructions and the Investor Undertaking, the Investor Undertaking shall govern.

Investors who have on or before the Early Consent Deadline entered into an Investor Undertaking in the manner set out herein will be eligible to receive an Early Consent Fee.

Instructions for Certificated Holders

In order to agree to the Investor Undertaking and receive the Early Consent Fee, Investors that are direct holders of Ordinary shares or C shares issued by the Public Fund (i.e. that do not hold Depository Interests through CREST) must submit a PDF of a signed copy of the attached Investor Undertaking and a PDF of the power of attorney or other authority (if any) under which it is signed, or a notarised or otherwise certified copy of such power or authority, **to Markel CATCo by email at the following address investornotifications@markelcatco.com by no later than 11.59 p.m. ADT on October 22, 2021.**

Help

You can find more information at <https://catcobuyout.alixpartners.com>. Any questions should be directed to Link Group at the email address operationalsupportteam@linkgroup.co.uk or telephone number +44371 664 0321.

**INSTRUCTIONS TO INVESTORS IN THE
CATCO REINSURANCE OPPORTUNITIES FUND LTD.
ENTERING INTO AN INVESTOR UNDERTAKING**

26 October 2021

On September 27, 2021, Markel CATCo Investment Management Ltd. (“**MCIM**”) announced the terms of a transaction that provides for an early return of substantially all net asset value (“**NAV**”) to persons who are beneficially interested in the shares of CATCo Reinsurance Opportunities Fund Ltd. (the “**Public Fund**” and such persons, the “**Investors**”) and also allows Investors to retain the right to receive any upside at the end of the current run-off period if currently held reserves are more than sufficient to pay claims (the “**Buy-Out Transaction**”). As part of the implementation of the Buy-Out Transaction, the Public Fund intends to propose a scheme of arrangement pursuant to Section 99 of the Companies Act (the “**Scheme**”).

On October 26, 2021, MCIM announced that Markel Corporation has agreed certain improvements to the terms of the Buy-Out Transaction which result in a significant increase in the return to all investors. The improved terms are set out in the term sheet attached to the support undertaking (the “**Investor Undertaking**”).

As described in the announcement and to allow for Investors who have not yet returned Investor Undertakings to consider these improved terms and be eligible to receive at completion an early consent fee equal to two percent (2%) of the Investor's current NAV (the “**Early Consent Fee**”), the deadline for Investors to enter into an undertaking to support the Buy-Out Transaction has now been **extended to 11.59 p.m. ADT on November 9, 2021** (the “**Extended Early Consent Deadline**”).

The announcements and additional information regarding the Buy-Out Transaction is available on the following website <https://catcobuyout.alixpartners.com>.

These instructions set out how Investors can confirm their acceptance of the Investor Undertaking.

You are or may be an Investor entitled to vote on the Scheme, and/or are a nominee or custodian for an Investor or hold an interest in shares of the Public Fund on behalf of Investors. If you are holding interests in the Public Fund on behalf of one or more Investors, you should promptly forward a copy of these materials to all persons on whose behalf you hold an interest, so they may instruct you to enter into the Investor Undertaking on their behalf. If you have assigned, sold, or otherwise transferred, or assign, sell or otherwise transfer, your interests as an Investor before the Extended Early Consent Deadline, you must forward these materials at once to the person or persons to whom you have assigned, sold or otherwise transferred, or assign, sell or otherwise transfer, your interests as an Investor.

Please note that although these instructions contain brief descriptions of some of the terms of the Investor Undertaking, Investors should not rely on these descriptions alone and should instead review the Investor Undertaking, which is available on the transaction website (<https://catcobuyout.alixpartners.com>). If there are any discrepancies between these instructions and the Investor Undertaking, the Investor Undertaking shall govern.

Investors who have on or before the Extended Early Consent Deadline entered into an Investor Undertaking in the manner set out herein will be eligible to receive an Early Consent Fee.

Instructions for Certificated Holders

In order to agree to the Investor Undertaking and receive the Early Consent Fee, Investors that are direct holders of Ordinary shares or C shares issued by the Public Fund (i.e. that do not hold Depository Interests through CREST) must submit a PDF of a signed copy of the attached Investor Undertaking and a PDF of the power of attorney or other authority (if any) under which it is signed, or a

notarised or otherwise certified copy of such power or authority, to Markel CATCo by email at the following address investornotifications@markelcatco.com by no later than 11.59 p.m. ADT on November 9, 2021.

Help

You can find more information at <https://catcobuyout.alixpartners.com>. Any questions should be directed to Link Group at the email address operationalsupportteam@linkgroup.co.uk or telephone number +44371 664 0321.

INVESTOR DEED OF UNDERTAKING

To: CATCo Reinsurance Opportunities Fund Ltd.

From: *Investor*: _____

Address: _____

_____ 2021

Acceptance, and undertaking in support, of the Buy-Out Transaction and Restructuring Proceedings

1. We have a beneficial interest in the shares in the capital of CATCo Reinsurance Opportunities Fund Ltd. (the “**Public Fund**”) set out on Schedule 1 (collectively, the “**Shares**”) with full power and authority to enter into this Undertaking and vote our Shares, interests or claims related to the Public Fund, or direct the voting of such Shares, interests or claims.

2. We understand that the Public Fund, together with Markel Corporation, has proposed the Buy-Out Transaction (the “**Buy-Out Transaction**”) substantially as described in the term sheet in Annex I (the “**Term Sheet**”).

3. The Buy-Out Transaction will be implemented by way of, and is conditional upon, approval of schemes of arrangement (the “**Schemes**”) under the Bermuda Companies Act 1981 (the “**Act**”) to be proposed by each of the Private Fund and the Private Fund (together, the “**Scheme Companies**”). The Schemes will be supported by petitions for the appointment of provisional liquidators in Bermuda to the Scheme Companies, Markel CATCo Investment Management Ltd. (the “**Manager**”) and Markel CATCo Re Ltd. (the “**Reinsurer**”) and petitions for recognition of the provisional liquidation proceedings and Schemes under chapter 15 of the United States Bankruptcy Code (collectively with the Schemes, the “**Restructuring Proceedings**”).

4. We are direct or indirect investors in the Public Fund Shares listed in Schedule 1 and are supportive of the Buy-Out Transaction and Restructuring Proceedings. We execute this Undertaking to confirm that we will take all actions necessary to assist in the implementation of the Buy-Out Transaction and Restructuring Proceedings.

Undertakings

5. By our signature below, we evidence our support of the Buy-Out Transaction and Restructuring Proceedings and agree:

(a) to cooperate in good faith with the Scheme Companies and the Purchaser (as defined in the Term Sheet), including complying with any reasonable request for information, and use commercially reasonable endeavours to successfully implement the Buy-Out Transaction and Restructuring Proceedings in accordance with this Undertaking and the Term Sheet;

(b) to attend (either in person or by proxy or otherwise) any meeting of the relevant Scheme Company in which we hold Shares, convened by court order to consider and approve the relevant Scheme (the “**Scheme Meeting**”);

(c) to vote all of our claims or interests related to the Public Fund in favour of any Scheme, whether (without limitation) in connection with the Shares set out in Schedule 1 or in our capacity as

potential creditors of any Scheme Company, including in any relevant class in any Scheme, any resolution or other matter requiring our approval to implement the Buy-Out Transaction, and execute and timely deliver any proxy document, form of direction, form of instruction, account holder letter or any other form for voting purposes, or any notice, in order to implement the Buy-Out Transaction and any Restructuring Proceeding, including any forms of proxy, forms of direction or account holder letter (or similar) accompanying the explanatory statement to be issued by the relevant Scheme Company with respect to any Scheme (the “**Scheme Document**”) within ten days after the publication of the Scheme Document;

(d) not to take, assist, support or encourage any Person to take, any action reasonably likely to delay, impede, frustrate or prevent the implementation and consummation of the Buy-Out Transaction or any Restructuring Proceeding, including:

(i) any challenge or objection to the Buy-Out Transaction, any Scheme or any other Restructuring Proceeding or any other process which is proposed in connection with implementation of the Buy-Out Transaction or a Restructuring Proceeding, or

(ii) the commencing or threatening of any claim or litigation in any jurisdiction against the Purchaser, the Scheme Companies, the Manager, the Reinsurer or any of their affiliates or their respective current or former employees, officers, directors or agents.

6. By delivering this Undertaking and by way of security for our obligations hereunder, we irrevocably appoint any director or provisional liquidator of the Scheme Companies severally as our attorney for the purposes of executing a form of proxy and doing all such other acts and things as may be lawful and necessary to ensure compliance with this Undertaking, provided that such appointment shall not take effect until the tenth day after the publication of the Scheme Document and only then if we have failed to comply with our obligations in paragraph 5(c) above. We undertake to ratify and confirm whatsoever our attorney shall lawfully do or cause to be done by virtue of this power of attorney. The granting of this power of attorney is without prejudice to our right to attend and vote in person at any Scheme Meeting, and any proxy form executed pursuant to this paragraph 6 or paragraph 5(c) above shall be disregarded if we actually attend and vote in person at any Scheme Meeting however a vote against any Scheme will be a breach of this Undertaking.

7. Notwithstanding paragraphs 6 to 7 above, we shall not be required (a) to take any action, or procure that any action which is prohibited or otherwise restricted by applicable law, regulatory requirement or by any order or direction of any court or governmental or regulatory body or (b) to incur any out-of-pocket expenses or other financial obligations that are not otherwise addressed in the Term Sheet.

Miscellaneous

8. We hereby acknowledge that this Undertaking and our rights and obligations under it shall be subject to the standard terms set out in Annex II. Each of our obligations under this Undertaking shall continue to apply notwithstanding the invalidity of any provision of the standard terms.

9. We agree that damages may not be an adequate remedy for breach of this Undertaking and accordingly each of the Scheme Companies, the Purchaser, the Manager and the Reinsurer shall be entitled to seek the remedies of specific performance or injunctive relief in respect of any such breach.

10. We agree that any delay by a Scheme Company in exercising, or failing to exercise, any right or remedy under this Undertaking shall not constitute a waiver of such right or remedy. We agree that a Scheme Company’s rights and remedies under this Undertaking are cumulative and not exclusive of any rights or remedies provided by law.

SCHEDULE 1

Investor Name: _____

Investor Code: _____

Address: _____

Contact: _____

(Please insert full name(s), address(es) and contact detail in **BLOCK CAPITALS**)

Number of C shares held	Number of Ordinary shares held

This document has been executed as a deed and is delivered and takes effect on the date stated at the beginning of it.

EXECUTED and **DELIVERED** as a **DEED**

By: _____

Name: _____

Title: _____

For and on behalf of:

In the presence of:

Witness Name: _____

Address: _____

Occupation: _____

ANNEX I

Term Sheet

SUBJECT TO CONTRACT

INVESTOR BUY-OUT TERM SHEET

This Term Sheet sets out the proposed terms for the early return of Net Asset Value (“NAV”) in the side pocket investments (the “**Side Pockets**”) held at Markel CATCo Re Ltd. (the “**Reinsurer**”), together with a premium, for the benefit of investors (the “**Investors**”) who hold shares in:

- a) funds of Markel CATCo Reinsurance Fund Ltd. (the “**Private Fund**”), which include direct investments made in each segregated account of the Private Fund other than the Aquilo Fund, including the Markel CATCo Diversified Fund (the “**Master Fund**”), Diversified Fund II, Limited Diversified Arbitrage Fund, Diversified Arbitrage Fund, GTL Diversified Fund, Markel Diversified Fund and QIC Diversified Fund (collectively, the “**Retro Funds**”, and such investors in the Retro Funds, the “**Retro Fund Investors**”),
- b) CATCo Reinsurance Opportunities Fund Ltd. (the “**Public Fund**,” and such investors, the “**Public Fund Investors**”), which invests directly in the Master Fund, and
- c) the Aquilo Fund, a segregated account of the Private Fund (such investors in the Aquilo Fund, the “**Aquilo Investors**”).

As set out in detail below, the early return of NAV to the Retro Fund Investors and Public Fund Investors on the Closing Date (as defined below) will be funded by (i) the Available Distribution Amount (as defined below), (ii) the Retro Fund Cash (as defined below) and (iii) the Buy-Out Amount (as defined below) provided by an affiliate of Markel Corporation (the “**Purchaser**”, and the Markel Affiliates funding the Purchaser, the “**FundingCos**”). The early return of NAV to the Aquilo Investors will be funded through a combination of funding from the Purchaser (through the FundingCos) and the release of contractually trapped cash currently held by fronting reinsurers of the Aquilo Fund, which shall be made possible by Markel Corporation, through a wholly-owned designee, providing adverse development cover to the fronting reinsurer. The premium paid to all Investors will be the Additional Consideration described below and funded by Markel Corporation or one of its affiliates.

Buy-Out of Retro Fund Investors	<p>The Investors in the Retro Funds will be entitled to a total return of 102% of Closing NAV (defined below) including an Early Consent Fee plus (i) a distribution in cash equal to their proportional entitlement to \$34 million (the “Additional Consideration”) and (ii) any Upside.</p> <p>At the date of completion (the “Closing Date”), Retro Fund Investors (including the Public Fund) will receive an aggregate accelerated return of the following proportion of Closing NAV for each Side Pocket:</p> <p style="padding-left: 40px;">100% for 2016 Side Pocket, 100% for 2017 Side Pocket, 100% for 2018 Side Pocket, and 100% for 2019 Side Pocket,</p> <p>(the “Accelerated Distribution Amount”), plus their proportionate amount of the Additional Consideration and the Early Consent Fee, if applicable.</p> <p>As a result of the payment of the Accelerated Distribution Amount, on the Closing Date:</p> <p style="padding-left: 40px;">Public Fund Investors holding Ordinary Shares will receive an estimated accelerated return of approximately \$0.32 per Ordinary Share (totaling</p>

	<p>approximately \$48.3 million of Closing NAV (as of 31 August 2021) including an Early Consent Fee and Additional Consideration).</p> <p>Public Fund Investors holding C Shares will receive an estimated accelerated return of approximately \$0.51 per C Share (totaling approximately \$42.2 million of Closing NAV (as of 31 August 2021) including an Early Consent Fee and Additional Consideration).</p>
Closing NAV	<p>Closing NAV will be Current NAV,</p> <p><u>plus</u> \$15 million released from a current contingent reserve held by the Private Fund, which will be primarily applied to fund the payment of Transaction Costs (as defined below),</p> <p><u>plus</u> \$20 million cash contribution from Markel Corporation or one of its affiliates,</p> <p><u>less</u> the remaining Administrative Expenses (as defined below), which will be reserved on the Closing Date.</p> <p>Additionally, for the Closing NAV with respect to the Public Fund, cash on hand will also be deducted.</p> <p>"Current NAV" means the current NAV available as at the most recent month end prior to the Closing Date, provided that this amount may never be less than NAV as of 31 August 2021.</p>
Buy-Out Amount of Retro Fund Investors	<p>In order to fund the buy-out of Retro Fund Investors, the Purchaser will purchase shares in the Reinsurer from the Private Fund for a cash purchase price (the "Buy-Out Amount") equal to the Accelerated Distribution Amount:</p> <p>less the amount of funds, if any, that are available for distribution to Retro Fund Investors that have been released from each Side Pocket of the Reinsurer and approved for distribution by the Bermuda Monetary Authority but not yet returned to the Retro Fund Investors in that Side Pocket, as at the last day of the month prior to the Closing Date (the total of all such amounts across all Side Pockets of the Reinsurer in the aggregate, the "Available Distribution Amount"),</p> <p>less the aggregate amount of cash, if any, that is held at each Retro Fund (other than the Administrative Expenses) to cover operating and other costs of that Retro Fund (the total of amount of consolidated cash at the Retro Funds being the "Retro Fund Cash").</p> <p>The Additional Consideration will be funded by Markel Corporation or one of its affiliates on the Closing Date.</p>
Return to Aquilo Investors	<p>Aquilo Investors will be entitled to a total return of 102% of Closing NAV plus (i) the Additional Consideration and (ii) any Upside.</p> <p>On the Closing Date, Aquilo Investors will receive a distribution in cash equal to their proportional entitlement to 100% of Closing NAV of the Aquilo Fund (the "Aquilo Accelerated Distribution Amount") plus their proportionate amount of the Additional Consideration and the Early Consent Fee, if applicable.</p>
Aquilo Buy-Out Amount of Aquilo Fund Investors	<p>In order to fund the buy-out of Aquilo Fund Investors, the Purchaser will purchase shares in the Reinsurer from the Private Fund for a cash purchase price (the "Aquilo Buy-Out Amount") equal to the Aquilo Accelerated Distribution</p>

	<p>Amount less the amount of trapped cash released in connection with any adverse development cover provided by Markel Corporation, through a wholly-owned designee, to a fronting reinsurer in respect of the assets of the Aquilo Fund.</p> <p>The Additional Consideration will be funded by Markel Corporation or one of its affiliates on the Closing Date.</p>
<p>Administrative Expenses</p>	<p>Administrative Expenses will be funded from cash reserves deducted from Current NAV on or before the Closing Date and allocated as set out below, including:</p> <ol style="list-style-type: none"> 1. Transaction Costs: costs for implementation of the deal, which are currently estimated to be approximately \$15 million. 10% of these costs will be allocated pro rata to the Aquilo Fund with the remaining Transaction Costs allocated pro rata to each Side Pocket. Transaction Costs are estimates only and the actual amount of fees incurred will be paid. 2. Ordinary Course Fees: estimated operating and other fees for the remaining run-off of the Markel CATCo business, which are currently estimated to be approximately \$14 million. These costs will be allocated among the Aquilo Fund and each Side Pocket based on a weighted pro rata distribution determined by “time to run-off.” <p>For example, Side Pocket 2019 is estimated to have the most time for final run-off, so will have a larger proportion of fees allocated to it.</p> <p>Ordinary Course Fees related to the operation of the Public Fund are allocated among the Public Fund Investors only.</p> 3. Reserve: an additional reserve of approximately \$5.8 million, which will be an amount equal to 20% of the total Transaction Costs and Ordinary Course Fees allocated to the Aquilo Fund and each Side Pocket. <p>After closing, no additional fees or expenses will be deducted from distributions of Closing NAV and there will be no continuing management fees charged by the Manager (any such fees will have been accelerated and included in the Ordinary Course Fees for the run-off of the Funds).</p> <p>After closing, additional fees or expenses arising in respect of the Aquilo Fund that are not covered by the reserve will be deducted from distributions to Aquilo Fund Investors.</p> <p>Any amounts reserved for Administrative Expenses remaining after wind down of the Public Fund, the Private Fund, the Manager and the Reinsurer will be returned to relevant Investors.</p>
<p>Upside Distributions</p>	<p>After the Closing Date, if and when any capital is released (i) in excess of the Buy-Out Amount allocable to a particular Side Pocket of the Reinsurer or (ii) in excess of the Aquilo Buy-Out Amount allocable to the Aquilo Fund, and in each case approved for distribution by the Bermuda Monetary Authority, each relevant Public Fund and Private Fund Investor shall be entitled to receive the amounts distributed. Distributions, if any, will occur one time per annum or more at the discretion of the Manager.</p> <p>Upon receiving a return from the Private Fund as contemplated in this provision,</p>

	the Public Fund will distribute the proceeds to the Public Fund Investors in accordance with its ordinary practices.
Information Rights	Investors will receive monthly Manager's Reports setting out remaining NAV for each Side Pocket at the relevant month end and the amount of capital released, including the amount that will be used to repay the Buy-Out Amount and the amount that will be returned to Investors.
Early Consent Fee	Investors that support the proposal set out in this Term Sheet by agreeing to the terms of the Investor Deed of Undertaking, in accordance with the instructions accompanying the Undertaking, shall receive on the Closing Date a cash fee in an amount equal to 2% of their proportional amount of Current NAV at the Closing Date (provided that they comply with the terms of their undertaking) (the " Early Consent Fee ").
Work Fee	(i) Funds managed by PKA A/S and (ii) Almitas Capital will be entitled to a cash fee in an amount equal to 2% of their proportional amount of Current NAV at the Closing Date. The work fee will be paid by the Private Fund and/or the Public Fund and funded by Markel Corporation or one of its affiliates.
Release	<p>To enable the early return of NAV to the Investors, and as a condition to and in consideration of the foregoing, each Investor, the Purchaser, Markel Corporation, the FundingCos, the Manager, the Private Fund (in respect of itself and all of its segregated accounts), the Public Fund and the Reinsurer (in respect of itself and all of its segregated accounts) shall provide an irrevocable and unconditional mutual release of each and every claim of any nature it may have against each of the Released Parties related to the business of the Reinsurer, the Private Fund, the Public Fund and the Manager and the Investors' shares.</p> <p>"Released Parties" means each Investor, the Purchaser, the FundingCos, Markel Corporation, the Private Fund (in respect of itself and all of its segregated accounts), the Public Fund, the Reinsurer (in respect of itself and all of its segregated accounts), the Manager and each of their former and existing affiliates, directors, managers, shareholders, officers, controlling persons, beneficial owners or interest holders, advisory board members, employees, consultants, agents, subsidiaries, members, managers, predecessors and successors in interest, heirs, executors and assignors or assignees, nominees, participants, partners, limited partners, general partners, principals, fund advisors, attorneys, financial advisors, investment bankers, accountants, other professionals or representatives, sub-advisors (and their respective affiliates directors, managers, shareholders, partners, principals, members, officers, controlling persons, employees and agents), and agents (including any individual who serves at the Manager's request as a director, officer, partner, trustee, or the like of another entity) and/or the legal representatives and controlling person of any of them.</p>

ANNEX II

Standard Terms

These Standard Terms will apply to the Undertaking and each other undertaking in support of the Buy-Out Transaction and Restructuring Proceedings in substantially similar form to the Undertaking executed by a beneficial holder, registered holder, nominee or depository interest holder in of either of the Scheme Companies (each such holder, a “**Consenting Investor**” and collectively the Undertaking and each other undertaking, the “**Investor Undertakings**”).

Definitions

“**Act**” has the meaning given to it in the Investor Undertakings.

“**Buy-Out Transaction**” has the meaning given to it in the Investor Undertakings.

“**Consenting Investor**” means a beneficial holder, registered holder, nominee or depository interest holder of either of the Scheme Companies who has executed an Investor Undertaking or accepted the terms of the Investor Undertaking by an escrow election through CREST and each other undertaking executed or accepted through CREST in support of the Buy-Out Transaction in a substantially similar form to the Undertaking.

“**Consenting Shares**” means the aggregate of (i) the various classes and sub-series of side pocket shares issued in the capital of each fund of the Private Fund set out in Schedule 1 under the heading “Ending Shares” of each Investor Undertaking and (ii) the various classes of shares issued (and depository interests in respect of those shares) in the capital of the Public Fund that are subject to the terms of an Investor Undertaking, either pursuant to an executed Investor Undertaking or held in escrow by the Registrar as elected through CREST.

“**Early Consent Fee**” has the meaning given to it in the Term Sheet.

“**Explanatory Statement**” means the explanatory statement(s) filed by the Scheme Companies in connection with the Schemes.

“**Majority Consenting Investors**” means Consenting Investors whose Consenting Shares aggregate at the relevant time more than fifty percent (50%) of the Consenting Shares.

“**Manager**” has the meaning given to it in the Investor Undertakings.

“**Material Adverse Event**” means an event or circumstance which materially effects the value of the Investors’ interests as a whole in the Private Fund and the Public Fund other than any event or circumstance arising out of or in connection with any claim filed by an investor against the Private Fund, the Public Fund, the Manager or any other Released Party (as defined in the Term Sheet) that will be released pursuant to the Schemes.

“**Private Fund**” means Markel CATCo Reinsurance Fund Ltd., a mutual fund company of unlimited duration with limited liability incorporated in Bermuda under the Companies Act 1981 of Bermuda (as amended) with registered number 50599 and registered office at Crawford House, 50 Cedar Avenue, Hamilton HM 11 Bermuda.

“Public Fund” means CATCo Reinsurance Opportunities Fund Ltd., an exempted mutual fund company incorporated in Bermuda under the Companies Act 1981 of Bermuda (as amended) with registered number 44855 and registered office at Crawford House, 50 Cedar Avenue, Hamilton HM 11 Bermuda.

“Purchaser” has the meaning given to it in the Investor Undertakings.

“Registrars” means the Link Group, as the registrar for the Public Fund, and Centaur Fund Services (Bermuda) Limited, as the registrar for the Private Fund.

“Reinsurer” has the meaning given to it in the Investor Undertakings.

“Restructuring Documents” means all documents, instructions, notices, agreements and instruments required to implement the Buy-Out Transaction and Restructuring Proceedings.

“Restructuring Effective Date” means the first date on which all Restructuring Documents have become effective in accordance with their terms.

“Restructuring Proceedings” has the meaning given to it in the Investor Undertaking.

“Scheme Companies” means the Private Fund and the Public Fund.

“Scheme Document” has the meaning given to it in the Investor Undertakings.

“Scheme Meeting” has the meaning given to it in the Investor Undertakings.

“Schemes” has the meaning given to it in the Investor Undertakings.

“Term Sheet” has the meaning given to it in the Investor Undertakings.

Dealings with Consenting Shares

1. Each Consenting Investor undertakes to the Scheme Companies that before the Schemes become effective it shall not itself or permit any registered holder (if different) to:
 - a. sell, transfer, charge, encumber, grant any option over or otherwise dispose of (**“Transfer”**) its Consenting Shares or any interest of any sort in, or with respect to, its Consenting Shares other than pursuant to the Scheme;
 - b. accept any other offer (however implemented) in respect of the Consenting Shares; or
 - c. enter into or solicit any person to enter into any agreement or arrangement (other than the Scheme) or incur any obligation to Transfer the Consenting Shares or that may restrict or impede it complying with the terms of the Investor Undertaking.

Documentation

2. Each Consenting Investor consents to the Scheme Companies, the Manager and the Purchaser referring to the aggregate amount of Consenting Shares subject to Investor Undertakings, as a percentage of the total shares issued by the Scheme Companies, from time to time in (a) any announcement relating to the Buy-Out Transaction and (b) any Restructuring Document.
3. Neither the Scheme Companies, the Manager nor the Purchaser shall disclose the identity of any Consenting Investor or any individual legal and beneficial holdings of a Consenting Investor unless such disclosure is

required to be made by court order or to a regulatory authority, including the Bermuda Monetary Authority, the Bermuda Stock Exchange or the London Stock Exchange.

4. Each Consenting Investor shall promptly give the Scheme Companies or the Purchaser all information and any assistance as may reasonably be required for the preparation of any announcement or document in order to comply with the requirements of any court, the Bermuda Monetary Authority, the Bermuda Stock Exchange, the London Stock Exchange and any other legal or regulatory requirement or body. Each Consenting Investor shall immediately notify the Scheme Companies in writing of any material change in the accuracy or impact of any information previously provided to them by the Consenting Investor.

Termination

5. Each of the Investor Undertakings shall terminate automatically on the earlier of:
 - a. 11:59 p.m. (Bermuda time) on December 31, 2021 (or such later date as may be agreed pursuant to paragraph 8 of these Standard Terms); or
 - b. the Restructuring Effective Date.
6. The Investor Undertakings also may be terminated by Majority Consenting Investors giving written notice to the Private Fund if any of the following events occur:
 - a. the Majority Consenting Investors (acting in good faith) determine that a Material Adverse Event has occurred; and
 - b. the Majority Consenting Investors (acting in good faith) determine that the terms set out in the Explanatory Statement and any supplemental offering memorandum attached thereto are materially worse or prejudicial to their rights as compared to the terms set out in the Term Sheet.
7. The Investor Undertakings may also be terminated by mutual written consent between the Private Fund, the Purchaser and the Majority Consenting Investors.

Amendments

8. Any time, date or period mentioned in these Standard Terms may be extended by written agreement (including by email confirmation) between the Private Fund, the Purchaser and the Majority Consenting Investors.
9. No other amendment or variation will be made to these Standard Terms or the Investor Undertaking unless agreed by the Private Fund, the Purchaser and the Majority Consenting Investors.
10. At any time an amendment or variation is sought pursuant to paragraph 8 or 9, the Manager shall notify the Consenting Investors of the amount of Consenting Shares subject to Investor Undertakings at such time, as a percentage of the total shares issued by the Scheme Companies.

Role of the Registrars

11. The Registrars shall be responsible for, among other things, the receipt and processing of the Investor Undertakings and any other calculations, notifications, processing of documents or receiving and disseminating information as required from time to time in order to facilitate the implementation of the Buy-Out Transaction, and the decision of the Registrars in relation to any such reconciliations and calculations (as applicable) which may be required shall be final (in the absence of manifest error) and may not be disputed by any Consenting Investor.

12. In undertaking such reconciliation and calculation, either of the Registrars may request, and the relevant Consenting Investor shall promptly deliver, any such other evidence as may reasonably be required by that Registrar proving to the reasonable satisfaction of that Registrar:
- a. that it is legally entitled and able to control the exercise and the casting of votes, instructions and consents in relation to its Consenting Shares; and
 - b. with respect to a Consenting Investor, its entitlement to receive the Early Consent Fee in respect of any Consenting Shares of which it is the holder of record and in respect of which it claims such entitlement.

Partial Invalidity

13. If any provision of these Standard Terms is held to be invalid or unenforceable, then such provision shall (so far as it is invalid or unenforceable) be given no effect and shall be deemed not to be included in these standard terms, but without invalidating any of the remaining provisions. To the extent any provision of these Standard Terms is judicially determined to be unenforceable, a court of competent jurisdiction may reform any such provision to make it enforceable.

Governing Law

14. These Standard Terms and the Investor Undertaking and any dispute or claim (including non-contractual disputes or claims) arising out of, or in connection thereto, or their subject matter shall be governed by and construed in accordance with Bermuda law and the Consenting Investors irrevocably submit to the exclusive jurisdiction of the courts of Bermuda in relation to any matter arising therefrom.